LRG1 Drives Pathological Angiogenesis by Disrupting Neutrophil Mitochondrial Homeostasis in Bladder Cancer
Advanced Science · 2026
DOI: 10.1002/advs.76604 ↗At a glance
Journal article in Advanced Science, 2026. Written by Dongshan Chen and 8 co-authors. Institution: Department of Urology, Qilu Hospital of Shandong University, Jinan, China. Major MEDLINE topics: Urinary Bladder Neoplasms, Glycoproteins, Neutrophils, Neovascularization, Pathologic. 42 references. The full text is freely available (open access, CC BY 4.0). Funded by: Postdoctoral Innovation Program of Shandong Province, Youth Project of Shandong Provincial Natural Science Foundation, Shandong Provincial Natural Science Foundation General Program.
Abstract (original language)
Abnormal tumor vasculature creates a permissive microenvironment that fuels the malignant progression of bladder cancer (BCa). While Leucine‐rich alpha‐2 glycoprotein 1 (LRG1) is known to regulate angiogenesis, its specific role in remodeling the BCa microenvironment remains poorly defined.We integrated single‐cell RNA sequencing (scRNA‐seq) with bulk transcriptomic datasets to identify key cellular subclusters. Functional validation was performed using subcutaneous and orthotopic BCa mouse models, neutrophil depletion, DNase I treatment, and clinical specimens. The molecular interactome was mapped via pull‐down assays, mass spectrometry, and confocal imaging.LRG1 is significantly upregulated in BCa and correlates with hematogenous metastasis and poor prognosis. Mechanistically, tumor‐derived LRG1 binds to Annexin A2 (ANXA2) on neutrophils through its LRR domain, impeding the mitochondrial translocation of Akt and triggering mtROS‐dependent release of Neutrophil Extracellular Traps (NETs). These NETs directly cause vascular destabilization by stripping mural cell coverage. Blockade of the LRG1‐NETosis axis induces vascular normalization, effectively overcoming microenvironmental barriers to increase drug delivery and T‐cell infiltration, thereby profoundly sensitizing BCa to cisplatin and anti‐PD‐1 therapy.The LRG1‐neutrophil‐NETosis axis is a critical driver of vascular dysfunction and therapeutic resistance in BCa. Targeting this axis represents a promising translational strategy to improve clinical outcomes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
- Shandong Academy of Pharmaceutical Sciences, Jinan, China.
- College of Foreign Languages, Shandong University of Traditional Chinese Medicine, Jinan, China.
- Biomedical Sciences College, Shandong First Medical University, Jinan, China.
ORCID profiles: Dongshan Chen
Funding
- Postdoctoral Innovation Program of Shandong Province
- Youth Project of Shandong Provincial Natural Science Foundation
- Shandong Provincial Natural Science Foundation General Program
- National Natural Science Foundation of China under the Young Scientists Fund
- Shandong Pingzheng Biotechnology Co., Ltd.
Cite
APA
Chen, D., Zhang, C., Xue, S., Zeng, Y., Cui, H., Wang, C., Feng, J., Yan, L., & Zang, Y. (2026). LRG1 Drives Pathological Angiogenesis by Disrupting Neutrophil Mitochondrial Homeostasis in Bladder Cancer. Advanced Science. https://doi.org/10.1002/advs.76604
Vancouver
Chen D, Zhang C, Xue S, Zeng Y, Cui H, Wang C, et al. LRG1 Drives Pathological Angiogenesis by Disrupting Neutrophil Mitochondrial Homeostasis in Bladder Cancer. Advanced Science. 2026. doi:10.1002/advs.76604
BibTeX
@article{Chen2026,
author = {Chen, Dongshan and Zhang, Cong and Xue, Song and Zeng, Yuan and Cui, Haochen and Wang, Chenfei and Feng, Jiayi and Yan, Lei and Zang, Yuanwei},
title = {LRG1 Drives Pathological Angiogenesis by Disrupting Neutrophil Mitochondrial Homeostasis in Bladder Cancer},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76604}
}
EUVIMED